动态CD177/CD10比率用于感染诊断和危重病患者的死亡风险分层:一个前性队列研究

Jiamin Huang1, Keliang Xie2, Heyue Li1

  • 1Research Centre for Neutrophil Engineering Technology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, 215002, Jiangsu Province, China.

EBioMedicine
|December 28, 2025
PubMed
概括

CD177/CD10比率有效地区分了感染和非传染性炎症,并预测了败血症的结果. 这种新型生物标志物为重症监护患者提供了更好的诊断准确性和预后分层.